Pharsight

Drugs that contain Ambrisentan

1. Letairis patents expiration

LETAIRIS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474752 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(3 years from now)

US8377933 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(3 years from now)

US9549926 GILEAD Compositions and methods of treating pulmonary hypertension
Oct, 2031

(7 years from now)

Market Authorisation Date: 15 June, 2007

Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil; For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of a...

Dosage: TABLET;ORAL

How can I launch a generic of LETAIRIS before it's drug patent expiration?
More Information on Dosage

LETAIRIS family patents

Family Patents